Reward pathways connect the prefrontal cortex with many key brain regions, including ◆ neurotransmitter centers, limbic emotional areas, and the hypothalamus. In these circuits, some neurotransmitters, such as dopamine, norepinephrine, oxytocin, and ◆ melanocortins, cause sexual excitation whereas other neurotransmitters, such as serotonin, opioids, and endocannabinoids, inhibit sexual excitation in these same circuits. Drugs, hormones, and disorders that disrupt sexual desire may either reduce the ◆ neurotransmitters of sexual excitation or enhance the neurotransmitters of sexual inhibition. Potential treatments for reduced sexual desire are those that promote dopamine, oxytocin, or ◆ melanocortins or block serotonin in reward pathways. 
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Glutamate neurons in
PFC descend to brainstem neurotransmitter centers (raphe) where they directly stimulate serotonin (5-HT) release.
Prefrontal cortex (PFC) circuits utilizing glutamate as neurotransmitter may be overly active when sexual desire is low.
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3. When these prefrontal circuits are overly active, they also reduce dopamine (DA) activity.
1.
5.
The net result is excessive 5-HT activity and reduced DA activity.
The behavioral output from this circuit, via the nucleus accumbens back to PFC relayed from the thalamus says "I have a headache," which in truth is just an excuse, really meaning lack of sexual interest and desire.
4.
The overly active glutamate pathway reduces DA indirectly by stimulating inhibitory γ-aminobutyric acid (GABA) interneurons in both the ventral tegmental area (VTA) and the zona incerta (ZI) of the hypothalamus (which projects from within the hypothalamus to the medial preoptic area [MPOA] 
5.
The net result of e ective treatment is generally to reduce 5-HT activity, to increase dopamine activity, or both. 2, 5 In this case, the output from the nucleus accumbens back to PFC via the thalamus is now an expression of interest in sexual activity. No treatment is currently approved for low sexual desire, but many agents with the pharmacologic actions described here are used "o label" for this purpose, while more e ective agents with better evidence of safety and e cacy are being developed.
4.
Enhanced DA activity can also be mediated by agents that act directly on dopamine output (such as stimulants and bupropion), which can sometimes improve sexual desire. 5, 9 Drugs that block 5-HT 2C receptors may also enhance DA release and could theoretically improve sexual desire.
5,9 Finally, experimental treatments that stimulate oxytocin or melanocortin activity in the hypothalamus hold promise as treatments for low sexual desire.
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